Advertisement

COMMUNITY-POWERED, RADICALLY OPEN TECHNOLOGIES TO ACCELERATE ALZHEIMER’S DISEASE THERAPEUTIC DISCOVERY

      Late-Onset Alzheimer’s Disease (AD) is a complex disease with multifactorial genetic and environmental etiologies. As such, there is a pressing need to understand the full molecular complexity of the disease, in order to develop therapeutics that target multiple orthogonal AD etiologies. There are three major challenges associated with this endeavor: 1) identifying new molecular hypotheses and mechanisms, 2) vetting those hypotheses via independent experimental assessments, and 3) prioritizing which new molecular mechanisms to recommend for therapeutic development. We posit that technologies developed to empower community-driven solutions in a radically open way will be key to the overall success of creating new AD therapeutics.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'